Zai Lab Ltd  

(Public, NASDAQ:ZLAB)   Watch this stock  
Find more results for ZLAB
-0.13 (-0.41%)
Real-time:   11:14AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 31.50 - 32.42
52 week 23.80 - 35.74
Open 31.85
Vol / Avg. 45,657.00/584,091.00
Mkt cap 1.57B
P/E     -
Div/yield     -
EPS -1.02
Shares 49.31M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets - -72.95%
Return on average equity - -
Employees 50 -
CDP Score - -


1043 Halei Road, Zhangjiang Hi-Tech Park
+86-21-61632588 (Phone)
+86-21-61632570 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.